Perspective Therapeutics, Inc. filed a Form 8-K on November 6, 2026, disclosing that on November 5, 2026, the company issued a press release and posted presentations announcing incremental clinical trial data for its VMT-α-NET program at the NANETS 2026 Multidisciplinary NET Medical Symposium.

Key Highlights

  • Clinical data presented: Incremental data and analyses from the company's Phase 1/2a clinical trial of [212Pb]Bamzireotide Navoxetan ("VMT-α-NET") were announced on November 5, 2026.
  • Patient population: The trial involves patients with unresectable or metastatic somatostatin receptor type 2-expressing neuroendocrine tumors, according to the filing.
  • Conference venue: Data were presented at the NANETS 2026 Multidisciplinary NET Medical Symposium, held November 5-7, 2026 in Las Vegas, Nevada.
  • Multiple presentations filed: The company filed a press release (Exhibit 99.1), a Conference Presentation (Exhibit 99.2), and an Investor Presentation (Exhibit 99.3) as exhibits.
  • Investor presentation posted: An investor presentation regarding the company's disclosures at NANETS and certain other information regarding the VMT-α-NET program was also posted to the company's website on November 5, 2026.
  • Signed by CEO: The filing was signed by Johan (Thijs) Spoor, Chief Executive Officer, on November 6, 2026.

Perspective Therapeutics Reports Phase 1/2a VMT-α-NET Data at NANETS Symposium

Perspective Therapeutics, Inc. (NYSE American:CATX) filed a current report on November 6, 2026, under Item 8.01 (Other Events), disclosing that on November 5, 2026, the company issued a press release and posted presentations to its website in connection with the NANETS 2026 Multidisciplinary NET Medical Symposium. The symposium took place November 5-7, 2026 in Las Vegas, Nevada, according to the filing.

The filing states that the disclosed materials announced "incremental data and analyses" from the company's Phase 1/2a clinical trial of [212Pb]Bamzireotide Navoxetan, referred to as VMT-α-NET. The trial is focused on patients with unresectable or metastatic somatostatin receptor type 2-expressing neuroendocrine tumors. The company also posted a separate investor presentation on November 5, 2026, covering its NANETS disclosures and additional information about the VMT-α-NET program, as the filing describes.

Three exhibits were incorporated by reference: a press release dated November 5, 2026 (Exhibit 99.1), a Conference Presentation (Exhibit 99.2), and an Investor Presentation (Exhibit 99.3). The filing does not include the clinical data itself within the body of the 8-K; the substantive content is contained in the attached exhibits. The report was signed by Chief Executive Officer Johan (Thijs) Spoor on behalf of the registrant.

What Was Disclosed

Perspective Therapeutics filed an 8-K reporting that it publicly released incremental Phase 1/2a clinical trial data for its VMT-α-NET program at the NANETS 2026 symposium on November 5, 2026, with supporting materials filed as exhibits to the report.